🟢 92/100

This product looks safe

  • Niacin: 400mg is 11.4× the Tolerable Upper Intake Level (35mg)
  • 20% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 400mg is 11.4× the Tolerable Upper Intake Level (35mg)

Label Data

1 Caplet(s) Serving Size
90 Servings
Botanical with Nutrients Product Type
20% Evidence Coverage

Supplement Facts — Evidence Check

400 mg (2000% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 11.4× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 400mg UL 35mg
Commiphora mukul gum resin exudate
300 mg
Terminalia arjuna bark extract
100 mg
Saccharum officinarum
20 mg
Black Pepper fruit extract
5 mg

Other Ingredients

Dicalcium Phosphate Microcrystalline Cellulose Hydroxypropyl Methyl Cellulose Polyvinylpyrrolidone Magnesium Stearate Sodium Starch Glycolate Silicon Dioxide Propylene Glycol

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Use: Take one caplet twice a day.

⚠️ Warnings & Precautions

Precautions/Warnings: Do not use if bottle seal is missing, torn or damaged.

If you are pregnant, nursing, taking any medication or have a medical condition, consult your healthcare practitioner before taking any dietary supplement.

Keep out of reach of children.

Additional Information

Store in a cool place.

SUPPORT FORMULA

Gugulipid(R)

BioPerine(R)

Sustained Release Bi-Layer Technology

Product Details

UPC / SKU 7 67382 03347 6
DSLD Entry Date 2015-01-23
Product Type Botanical with Nutrients
Form Other (e.g. tea bag)
DSLD ID 41490
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →